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Abstract CT is currently the mainstay in staging malignant
lymphoma in children, but the risk of second neoplasms due to
ionizing radiation associated with CT is not negligible.
Whole-body MRI techniques and whole-body diffusion-
weighted imaging (DWI) in particular, may be a good
radiation-free alternative to CT. DWI is characterized by high
sensitivity for the detection of lesions and allows quantitative
assessment of diffusion that may aid in the evaluation of
malignant lymphomas. This article will review whole-body
MRI techniques for staging malignant lymphoma with
emphasis on whole-body DWI. Furthermore, future consid-
erations and challenges in whole-body DWI will be discussed.
Keywords Whole-body MRI . Diffusion-weighted
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Introduction
Cancer is the second most common cause of death among
children aged 0–14 years, surpassed only by accidents [1].
Of all childhood cancers, the malignant lymphomas
[Hodgkin disease (HD) and non-Hodgkin lymphoma
(NHL)] rank third in incidence, with an age-standardized
incidence rate of 15.5 per million [2]. Furthermore, in
adolescents (aged 15–19 years) the malignant lymphomas
are the leading cause of cancer, with an age-standardized
incidence of 47.4 per million [2]. Once a malignant
lymphoma has been diagnosed histologically, extent of
disease has to be assessed (i.e. staging), because this
determines treatment planning and prognosis, and knowing
all sites of involvement allows monitoring the effect of
therapy [3, 4]. Malignant lymphomas are staged using the
Ann Arbor staging system, except for childhood NHLs that
are staged using the Murphy staging system [3–6]. Initial
staging (at diagnosis) and restaging (after onset or comple-
tion of therapy or in cases of disease recurrence) is usually
done by means of CT or combined 18F-fluoro-2-deoxy-D-
glucose positron emission tomography FDG-PET/CT [7,
8]. FDG-PET/CT has a central role in the management of
childhood HD. However, FDG-PET does not form part of
the standard imaging protocol in childhood NHL, although
it is often performed in an ad hoc fashion. However, a
disadvantage of FDG-PET/CT is the patient’s exposure to
ionizing radiation that may lead to the development of
second neoplasms in later life [9]. This is especially
important in children and adolescents, because they are
inherently more radiosensitive than adults, and because
they have more remaining years of life during which a
radiation-induced cancer could develop [9].
Over the past decades outcome of children with
malignant lymphoma has improved considerably, with
long-term event-free survival rates of >90% in childhood
HD and >80% in childhood NHL [10, 11]. Current
treatment strategies for malignant lymphoma aim at
maximizing the chance of cure, while minimizing (late)
toxicity such as infertility, premature menopause, cardiac
disease, and most importantly, risk of second neoplasms
[10, 11]. Therefore, addressing the radiation risks from CT
is an important issue in this population. Using dedicated
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low-dose CT protocols in children may reduce the risk of
radiation-induced fatal cancer from CT [12]. An alternative
solution is to replace FDG-PET/CT by other radiation-free
imaging modalities, such as US or MRI [12]. In the context
of staging of malignant lymphoma, whole-body MRI may
be an excellent alternative to FDG-PET/CT, because it
allows cross-sectional imaging of the entire body, provides
a high soft-tissue contrast, and offers a wide arsenal of
anatomical and functional sequences. With regard to the
latter, whole-body DWI has recently been introduced as a
potentially useful functional imaging modality to evaluate
malignant lymphomas [13, 14]. Since some centres already
perform MRI for staging, DWI may be added to the routine
MRI protocol as a potentially valuable adjunct. In this
article, whole-body MRI techniques for staging malignant
lymphoma, and whole-body DWI in particular, will be
described and illustrated. Furthermore, future considerations
and challenges in whole-body DWI will be discussed.
Whole-body MRI techniques for staging malignant
lymphoma
Conventional whole-body MRI
Although there is no standard protocol for whole-body
MRI, and the definition of “whole-body MRI” is rather
arbitrary, it is usually performed or displayed in the coronal
plane, with a field of view (FOV) that provides coverage of
at least the area from the head/neck to the upper thighs
(Figs. 1 and 2) [15–18]. Previously, separate body regions
were imaged by repeatedly repositioning the patient [19].
However, this approach was time-consuming and uncom-
fortable for both the examiner and the patient. At present,
this limitation has been overcome by the widespread
availability of sliding table platforms that allow sequential
movement of the patient through the bore of the magnet
without patient repositioning [20]. Commonly applied
sequences for whole-body MRI include (contrast-medium
enhanced) T1-weighted (T1-W) and (fat-suppressed) T2-
weighted (T2-W) imaging, but there is no consensus yet on
which combination of sequences provides the highest
diagnostic accuracy while being time-efficient. Nonethe-
less, previous studies have shown the particular utility of
short inversion time inversion recovery (STIR) whole-body
MRI for staging malignant lymphoma [16–18].
STIR is a sensitive method for the detection of
parenchymal and bone marrow lesions, that are generally
highlighted as high signal intensity structures on this
sequence [16–18, 21]. However, malignant lymph nodes
cannot be differentiated from non-malignant nodes on the
basis of signal intensity yet, neither on T1-W nor T2-W
sequences. Thus, assessment of nodal involvement is still
based on size criteria on conventional MRI. So far, only
three studies have investigated the value of conventional
whole-body MRI for the staging of malignant lymphoma
[16–18]. Brennan et al. [16] performed a study in 23
adults that presented either for initial staging or restaging
of HD or NHL and reported that whole-body MRI using
STIR enables disease staging and that it compared
favourably with CT for the detection of lymph nodes
>12 mm in short-axis diameter and for the detection of
bone marrow involvement. Kellenberger et al. [17]
performed a small study in eight children for initial
staging and restaging of HD or NHL and reported that
whole-body MRI using STIR is a sensitive technique for
staging malignant lymphoma and that it is superior to
blind bone marrow biopsy and conventional imaging
(including CT, gallium-67 scintigraphy and bone scintig-
raphy) for the detection of bone marrow involvement at
initial diagnosis. However, whole-body MRI using STIR
was reported to lack specificity for diagnosing recurrent or
residual disease [17]. Finally, Kwee et al. [18] compared
whole-body MRI using both T1-W and STIR sequences to
CT for the initial staging of 31 patients with HD or NHL.
Staging results of whole-body MRI were equal to those of
CT in 74% (23/31), higher in 26% (8/31), and lower in 0%
(0/31) of patients, with correct/incorrect/unresolved over-
staging relative to CT in 3, 2 and 1 patient(s) respectively,
and incorrect staging of both modalities in 1 patient [18].
Results of these studies suggest that staging of malignant
lymphoma using whole-body MRI is feasible and prom-
ising, but definitive conclusions regarding its value in the
diagnostic management of malignant lymphoma cannot be
made yet [16–18].
Rationale for DWI
A disadvantage of conventional (T1- or T2-W) whole-body
MRI is the large amount of data that has to be evaluated,
including data from many normal structures such as fat,
muscles and vascular structures. Consequently, image
interpretation can be time-consuming and subtle lesions
may be overlooked. DWI, also known as intravoxel
incoherent motion imaging, may overcome this disadvan-
tage of conventional whole-body MRI. The most common
approach to render MRI sensitive to diffusion is by using a
spin-echo sequence and placing two strong gradients [so-
called motion-probing gradients (MPGs)] on either side of
the 180º refocusing pulse [22]. DWI is basically a T2-W
sequence, but the application of two strong MPGs results in
a decrease in signal intensity of all structures. Importantly,
the amount of signal intensity decrease induced by the
MPGs is not similar for all structures, but depends on the
degree of apparent diffusion that occurs between the MPGs;
structures with a relatively low diffusivity are less sup-
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pressed than tissues with a relatively high degree of
diffusion or perfusion (e.g. vascular structures, cerebrospi-
nal fluid and urine). Since most lesions (both benign and
malignant) exhibit a relatively impeded diffusion, they
generally lose less signal than surrounding normal back-
ground structures at DWI, resulting in a high lesion-to-
background contrast. Furthermore, fat suppression [that is
inherently necessary in echo-planar imaging (EPI) to avoid
image degradation due to severe chemical shift] also
improves lesion-to-background contrast. Thus, DWI may
increase lesion detection rate while decreasing image
interpretation time. As mentioned previously, DWI is
basically a T2-W sequence; consequently, residual T2
components (also known as T2 shine-through) can be seen
on DWI that may mimic areas of impeded diffusion. For
this reason, it is often recommended to review a
corresponding apparent diffusion coefficient (ADC) map
that does not contain any residual T2 components and
allows quantification of diffusion; this is especially impor-
tant in diagnosing acute ischaemic stroke [23]. However, in
order to create an ADC map, at least two datasets with
different degrees of diffusion-weighting (i.e. b-values) have
to be acquired. Furthermore, lesion-to-background contrast
on the ADC map is poor, and misregistration of the
different datasets obtained with different b-values may
occur (e.g. due to patient motion or image distortion).
Moreover, and perhaps more importantly, T2 shine-through
should not always be regarded as a disadvantage. In fact,
many lesions exhibit both a prolonged T2 value and an
impeded diffusion; both components contribute to the high
conspicuity of lesions at DWI.
DWI: from the brain to the body
Since the mid-1990s, DWI has developed into a well-accepted
method for the diagnosis of acute ischaemic stroke [23]. Of
note, in acute ischaemic stroke apparent diffusion is (most
likely) impeded due to cytotoxic oedema that gives high
signal at DWI [23, 24]. Previously, DWI outside the brain was
not routinely feasible because the use of EPI, that is necessary
for ultrafast imaging, could lead to severe image distortion in
the magnetically inhomogeneous body. This limitation has
relatively recently been overcome by the development of
stronger and faster gradients, and, most importantly, parallel
acquisition techniques that allow shortening of the echo-train
length in EPI, thereby reducing image distortion [25].
Whole-body DWI with background body signal
suppression: DWIBS
It was previously thought that diffusion-weighted contrast
could not be maintained during bulk tissue motion and, in
a b c
b
Fig. 1 15-year-old boy with stage II nodular sclerosing Hodgkin disease.
Coronal whole-body (a) T1-W, (b) STIR and (c) greyscale inverted MIP
DWI show cervical and mediastinal lymph node involvement (arrows).
Note normal high signal intensity of the spinal cord (arrowhead 1),
spleen (arrowhead 2), prostate (arrowhead 3) and testes (arrowhead 4)
at whole-body DWI. Also note insufficiently suppressed fat (arrowheads
5), not to be mistaken for pathologic lesions. Normal lymph nodes
(encircled) are also visualized at whole-body DWI
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particular, respiratory motion because diffusion takes place
over several micrometres during the period in which the
MPGs are applied, whereas respiratory motion takes place
on the order of centimetres. Thus, breath-hold or
respiratory-triggered DWI was considered necessary for
DWI of the chest and abdomen. However, in breath-hold
DWI, only thick slices (usually 8–10 mm) with relatively low
signal-to-noise ratio (SNR) can be obtained, that cannot be
used to create multiplanar reformats (MPRs) or 3-D displays
such as maximum intensity projections (MIPs).
Respiratory-triggered DWI does not have these disadvan-
tages, but can considerably prolong the scan time. Thus, both
breath-hold and respiratory-triggered DWI are not suitable for
a whole-body DWI examination. A major breakthrough for
whole-bodyDWIwas the proof of the feasibility of DWI under
free-breathing [13, 14]. The fact that a free-breathing
acquisition is feasible can be explained by the fact that
respiratory motion can be regarded as coherent motion during
the period in which the MPGs are applied, and as such does
not affect intravoxel incoherent motion (i.e. diffusion) [13,
14]. The concept of DWI under free-breathing was called
diffusion-weighted whole-body imaging with background
body signal suppression (DWIBS). The free-breathing ap-
proach allows thin slices (typically 4–5 mm) with multiple
signal averages (to increase SNR) to be obtained in a practically
acceptable scan time and the acquired dataset can be used to
create multiplanar reformats and 3-D displays. Furthermore, in
DWIBS, high b-values (typically 1000 s/mm2) are applied to
ensure sufficient suppression of background body signals
while highlighting lesions. Inverting the greyscale of DWIBS
images gives them the typical appearance of PET-like images
(Figs. 1, 2, 3, 4). Further details about the concept of DWIBS,
including its practical implementation and parameter settings,
can be read elsewhere [14].
Currently, a whole-body DWI examination can be
performed in approximately 20–30 min. When adding
conventional (T1- and T2-W) whole-body MRI, total
examination time can be approximately 45 min. Suggested
sequences for whole-body MRI/DWI at 1.5-T are listed in
Table 1. In our experience, children aged 8 years and older
tolerate such an examination very well, without the need for
any sedation [of note, most childhood malignant lympho-
mas occur in older children and adolescents (2)]. One
recent study compared a combination of conventional
whole-body MRI (T1-W and STIR sequences) and whole-
body DWI (without using any ADC mapping) to CT for the
staging of 28 patients with newly diagnosed HD or NHL
[18]. Staging results of combined conventional whole-body
MRI and whole-body DWI were equal to those of CT in
75% (21/28), higher in 25% (7/28), and lower in 0% (0/28)
cba
Fig. 2 17-year-old girl with unspecified widespread lymphoproliferative
disease. Coronal whole-body (a) T1-W, (b) STIR and (c) greyscale
inverted DWI show extensive (bilateral) cervical, axillary, paraaortic,
mesenteric, and pelvic lymph node involvement (continuous arrows).
Note relatively high signal intensity of the bone marrow (e.g. in both
femoral diaphyses (dashed arrows) suggestive of bone marrow
hyperplasia (reconversion). Also note insufficiently suppressed fat in
the right flank and buttock (arrowheads)
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of patients, with correct/incorrect overstaging relative to CT
in 6 and 1 patient(s), respectively. Interestingly, the
combination of conventional whole-body MRI with
whole-body DWI correctly upstaged 4 of 28 patients
compared to conventional whole-body MRI alone, that
well reflects the potential additional diagnostic value of
DWI [18]. Nevertheless, although these initial results
appear very promising compared to CT, more studies with
larger sample sizes are needed. Furthermore, whole-body
DWI has not yet been compared to FDG-PET/CT.
Whole-body DWI for staging malignant lymphoma;
specific considerations
Nodal pathology
One of the first observations made when DWI was applied
in the entire body was the clear visualization of lymph
nodes, that appear as high signal intensity structures, while
surrounding background tissues (including fat) are sup-
pressed (Figs. 1–4) [13]. For this reason it was thought that
one promising application of whole-body DWI could be in
staging of malignant lymphoma. However, one important
limitation of DWI is that it visualizes both non-malignant
and malignant lymph nodes (Fig. 1). This is because normal
lymph nodes already have a relatively low diffusivity
(probably due to high cellularity) and long T2 value.
Several studies have reported that lymphomatous lymph
nodes have lower ADCs than metastatic lymph nodes or
benign lymphadenopathy (probably due to increased cellu-
larity). However, these studies only included pathologically
enlarged lymph nodes without considering (normal-sized)
“healthy” lymph nodes [26–30]. Therefore, the value of
ADC measurements in discriminating (normal-sized)
“healthy” lymph nodes from (normal-sized) lymphomatous
lymph nodes is still unknown. In addition, one recent study
performed an inter- and intra-observer reproducibility study
regarding ADC measurements of normal-sized lymph
nodes [31]. The ranges of mean ADC difference±limits of
agreement (in 10-3 mm2/s) for inter-observer agreement
were -0.03–0.02±0.15–0.31. In addition, ranges of mean
ADC difference±limits of agreement (in 10-3 mm2/s) for
intra-observer agreement were 0.00–0.04±0.13–0.32 [31].
b
a
Fig. 4 12-year-old girl with stage I diffuse large B-cell lymphoma
arising in the pharyngeal tonsils (histologically proven). Coronal
whole-body greyscale inverted MIP DWI (a) shows no obvious nodal
or extranodal pathology, except for striking high signal intensity in
both pharyngeal tonsils (encircled). Although the normal Waldeyer
ring often exhibits high signal intensity at DWI (also shown in Fig. 3),
the corresponding axial image (b) shows size asymmetry of the
pharyngeal tonsils, indicating lymphomatous involvement
Fig. 3 16-year-old boy with stage IV nodular sclerosing Hodgkin
disease. Coronal whole-body greyscale inverted MIP DWI shows left
cervical, infraclavicular, and pelvic lymph node involvement (continuous
arrows), and left humeral, vertebral, and pelvic bone marrow
involvement (dashed arrows). Note that both pharyngeal tonsils
(encircled) also exhibit high signal intensity, but this is a normal finding
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Given this relatively large variability, inter- and intra-observer
reproducibility of ADC measurements of normal-sized lymph
nodes appears to be rather poor. Thus, the detection of
lymphomatous lymph nodes in whole-body DWI is still based
on size criteria. Nonetheless, compared to conventional (T1-
and T2-W) whole-body MRI, whole-body DWI provides a
faster and more straightforward evaluation of the amount and
distribution of (pathologically enlarged) lymphomatous
lymph nodes.
There are some potential pitfalls and drawbacks that
have to be taken into account when evaluating whole-body
DWI with respect to the evaluation of nodal/lymphoid
pathology. First DWI, and in particular DWIBS (that is
used for whole-body DWI), highlights lymph nodes while
suppressing surrounding normal structures. Because of the
lack of anatomical reference, size measurements of lymph
nodes at DWI are highly dependent on the applied window
level and window width. In addition, there are no published
studies comparing nodal measurements at DWI with those
at conventional imaging (either CT or T1- and T2-W
images). Thus, at present it is recommended that sizes of
lymph nodes that are suspicious for malignancy at DWI are
measured on conventional T1- or T2-W images for
verification. Nevertheless, the efficacy of such an approach
Table 1 Suggested sequences for whole-body MRI/DWI at 1.5-T.
SFR spectral fat saturation. 1DWI can be combined with either
spectral fat saturation (DWI-SFS) or a STIR pre-pulse (DWI-STIR)
for fat suppression. DWI-SFS offers higher SNR and is relatively less
time-consuming than DWI-STIR. However, DWI-STIR offers more
robust fat suppression over an extended FOV than DWI-SFS, because
STIR is less sensitive to magnetic field inhomogeneities. Because the
head, neck and shoulder regions usually suffer from considerable
magnetic field inhomogeneities, it is recommended to use DWI-STIR
for these body regions. In addition, DWI-STIR may be useful in
suppressing bowel signal that often has a short T1 relaxation time,
similar to that of fat. 2At present, it is recommended to perform DWI
in the axial plane and to coronally reformat the acquired dataset
afterwards, because direct coronal scanning may still suffer from
considerable image distortion due to the need for a larger FOV. 3A b-
value of 1000 s/mm2 is effective in suppressing background body
signals while highlighting lesions throughout the entire body.
Therefore, a b-value of 1000 s/mm2 can be recommended for whole-
body imaging. The relatively low signal at a b-value of 1000 s/mm2
can be increased by acquiring multiple signal averages. The additional
acquisition of a b-value of 0 s/mm2 allows quantitative diffusion
measurements. 4Effective scan time without taking into account the
time needed for acquiring survey scans, breath holding, respiratory
gating, table movements, and coil repositioning. 5Using DWI-SFS for
three stations covering the pelvis, abdomen and chest, and using DWI-
STIR for the station that covers the head, neck, and shoulder
Parameter T1-W STIR DWI-SFS1 DWI-STIR1
Pulse sequence Single-shot turbo spin-echo Single-shot spin-echo
echo-planar imaging
Repetition time (ms) 537 2444 6962 8612
Echo time (ms) 18 64 78
Inversion time (ms) – 165 180 –
Receiver bandwidth (Hz) 460.1 487.9 30.2
Slice orientation Coronal Axial2
Slice thickness (mm) 6.0 4.0
Slice gap (mm) 1.0 0.0
No. of slices per station 30 60
Cranio-caudal coverage per station (mm) 265 240
Field of view (mm2) 530×265 530×265 450×360
Acquisition matrix 208×287 336×120 128×81
Directions of motion probing gradients – Phase, frequency, and slice
B-values (s/mm2) – 0 and 10003
No. of signals averaged 1 2 3
Partial Fourier acquisition (%) – 0.651
Parallel acceleration factor – 2
Echo-planar imaging factor – 43
Respiratory motion compensation techniques Breath holding or respiratory gating are recommended
when scanning the chest and abdomen
Image acquisition under
free breathing
Acquired voxel size (mm3) 1.27×1.85×6.00 1.58×2.21×6.00 3.52×4.50×4.00
Reconstructed voxel size (mm3) 1.04×1.04×6.00 1.04×1.04×6.00 1.76×1.76×4.00
Effective scan time per station4 47 s 44 s 3 min 20 s 4 min 4 s
Total no. of stations 7 3 (+1) 5 4
Total effective scan time4 5 min 48 s 5 min 13 s 14 min 4 s5 16 min 26 s
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is still unknown. Another issue is that, unlike respiratory
motion, cardiac motion may result in non-rigid body
motion and signal loss of structures close to the heart [32,
33]. Consequently, the evaluation of mediastinal lymph
nodes may be affected by cardiac motion. Nevertheless,
relatively large mediastinal masses can readily be identified
at DWI (Fig. 1).
Extranodal pathology
DWI is a very sensitive method for the detection of
extranodal lymphomatous lesions that generally exhibit
high signal intensity at DWI (due to low diffusivity and
long T2) (Fig. 3). Importantly, several benign conditions
(including inflammatory and infectious lesions) also have
high signal intensity at DWI. To minimize the number of
false-positive results DWI should be interpreted along with
other sequences and patient history and findings on clinical
examination should be known when interpreting the
images. Although there are as yet no established criteria
for classifying lesions as negative or positive for lympho-
matous involvement, a signal intensity higher than that of
the spinal cord has often been proposed as suggestive of
malignancy [33–36]. On the other hand, diffusivity may be
increased in cases of necrosis (provided no haemorrhagic
components are present), that can be visualized as areas of
relatively low signal intensity at DWI.
Another important issue is that several normal extra-
nodal structures (including brain, salivary glands, Waldeyer
ring, thymus, spleen, gallbladder, adrenal glands, prostate,
testes, penis, endometrium, ovaries, spinal cord, peripheral
nerves, and bone marrow) (may) also exhibit high signal
intensity at DWI, due to their relatively low diffusivity and
long T2 value (Fig. 1) [13, 14]. In our experience, Waldeyer
ring in particular may appear very hyperintense at DWI
(Figs. 3, 4). Detection of abnormality in this organ based on
differences in signal intensity may be difficult, although an
asymmetrical appearance may suggest the presence of
lymphomatous involvement (Fig. 4). Another lymphoid
organ that often appears very hyperintense at DWI is the
spleen (Figs. 1–4). Consequently, abnormality in this organ
may be obscured. On the other hand, visibility of the spleen
is variable and probably dependent on its iron content (and
consequent signal loss). Similarly, the visibility of the liver
is related to its iron content, although this organ usually
appears relatively hypointense at high b-values (i.e.
≥1000 s/mm2). A potential pitfall in DWI is in the
evaluation of the bone marrow. During skeletal maturation,
haematopoietic (red) marrow is converted to fatty (yellow)
marrow [37]. At DWI, yellow marrow appears hypointense
thanks to the use of fat suppression. Red bone marrow
appears hyperintense at DWI, probably due to its high
cellularity that has a relatively impeded diffusion [38].
Residual or reconverted red bone marrow (islands) may
resemble lymphomatous bone marrow involvement (Fig. 2).
Thus, signal intensities of normal and lymphomatous bone
marrow may overlap at DWI [39]. Nevertheless, additional
conventional (T1- or T2-W) MRI sequences may increase
the diagnostic performance of DWI alone in the assessment
of the bone marrow. Despite its imperfect specificity, DWI
may have a role in ruling out bone marrow involvement and
guiding bone marrow biopsy [39, 40].
Other important body regions that require special
consideration are the liver and lung. Similar to bone
marrow involvement, liver or lung involvement, which are
not uncommon in malignant lymphoma, represent stage IV
disease [3, 4, 41, 42]. Usually, DWI of the liver is acquired
using breath-holding or respiratory triggering [43]. In
particular, the suppression of liver vessels in DWI is an
advantage over conventional MRI sequences and increases
sensitivity for the detection of lesions [44]. However, as
mentioned previously, whole-body DWI is acquired using
free-breathing. Despite the fact that the breathing approach
introduces slight image blurring due to diaphragmatic
motion, liver lesions can generally be well depicted thanks
to thin slice acquisition and the high degree of signal
averaging [45].
DWI of the lung is a particular challenge; besides cardiac
and respiratory motion artefacts, susceptibility-induced
image distortion and signal loss due to the many air-tissue
interfaces may occur. Nevertheless, although sensitivity of
CT still outperforms that of MRI/DWI in the lung, studies
in patients with pulmonary nodules have shown that DWI is
able to detect lung lesions up to 5 mm in diameter [34–36].
Moreover, unlike CT, DWI is able to provide functional
tissue information that may aid in the differentiation
between benign and malignant pulmonary lesions [34–36].
Of note, DWI has been shown to diagnostically outperform
FDG-PET in the characterization of pulmonary nodules/
masses [36]. Despite its promise, the diagnostic perfor-
mance of DWI in the detection of lymphomatous lung
lesions requires further investigation.
Role of imaging beyond staging
Imaging plays a crucial role in staging of malignant
lymphoma, but may also be of value in the (early)
assessment of response to therapy. Early assessment of
response to therapy will allow more individualized therapy
that will maximize the chance of cure while minimizing
risk of (late) toxicity. However, anatomic imaging modal-
ities such as CT, US and conventional MRI sequences may
not be sufficiently accurate in discriminating residual
disease from fibrosis or scar tissue [46–48]. FDG-PET, on
the other hand, provides functional tissue information, and
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may be superior to conventional imaging modalities in this
context. A recent study by Furth et al. [48] has indeed
shown that FDG-PET is superior to conventional imaging
methods (i.e. contrast-enhanced MRI of neck, abdomen,
and pelvis; US examinations of all lymph node regions; as
well as contrast-enhanced CT of the chest) with regard to
specificity in early (i.e. after two cycles of chemotherapy)
and late response assessment (i.e. after completion of
chemotherapy) in children with HD (68% versus 3%, and
78% versus 11%, respectively; both P <0.001). Specificity
of early therapy response assessment by FDG-PET was
improved to 97% by quantitative analysis of maximal
standardized uptake value reduction using a cut-off value of
58%. These data suggest that FDG-PET should not be
omitted either for staging or response assessment [48]. At
present it is still highly speculative whether DWI can
replace FDG-PET in the diagnostic management of malig-
nant lymphoma. Interestingly, a voxel-based quantitative
DWI approach [functional diffusion mapping, currently
referred to as parametric response mapping of diffusion
(PRMADC)] has recently shown promise to give an early
prediction of survival in patients with high-grade gliomas
[49, 50]. However, whole-body quantitative DWI techni-
ques still have to be developed and subsequently compared
to the current functional imaging modality of choice in
malignant lymphoma; FDG-PET.
Future considerations and challenges
Reducing image blurring
Diffusion-weighted contrast is maintained under free
breathing acquisition (i.e. DWIBS), although at the expense
of slight image blurring. Image blurring may affect
interpretation of paradiaphragmatic organs, such as the
liver. An effective approach to reduce image blurring in
DWIBS may be the use of a navigator echo technique that
allows continuous real-time slice tracking and position
correction, without the use of any gating window. Conse-
quently, image blurring is reduced without considerably
prolonging scan time. Implementing such a technique in a
whole-body DWI sequence for staging malignant lympho-
ma may be attractive, since it can improve visualization of
peridiaphragmatic organs [45, 51].
Whole-body DWI at 3.0-T
Whole-body DWI is currently best performed at 1.5-T, using a
phased-array receiver surface coil. Nevertheless, SNR in DWI
is relatively low, even though a high number of signal
averages can be acquired when using the concept of DWIBS.
SNR is increased when performing DWI at higher field
strength, since SNR increases linearly with field strength [52].
This in turn may improve staging accuracy in malignant
lymphoma. A recent feasibility study showed that DWIBS at
3.0-T offers higher SNR compared to that at 1.5-T, but the
former still suffers from a higher risk of B0 and B1
inhomogeneities and susceptibility artefacts [53]. Therefore,
the further development of multi-source radiofrequency (RF)
transmission technology (that will be discussed later) and
non-EPI-based DWI techniques is important to solve these
problems [54, 55]. Another challenge at high field strength is
fat suppression; inadequately suppressed fat may hinder
image interpretation. Compared to a frequency selective
(spectral fat saturation) pre-pulse, a short inversion time
inversion recovery (STIR) pre-pulse has been shown to offer
the best fat suppression in all body regions at 3.0-T, since the
latter is less sensitive to B0 inhomogeneities [53]. However,
the use of STIR inherently yields lower SNR than the use of
spectral fat saturation [56]. Furthermore, both spectral fat
saturation and STIR require additional RF and/or gradient
pulses, thereby increasing the specific absorption rate (SAR)
and prolonging scan time [56].
Thus, the development of new fat suppression techniques is
important to exploit the full potential of whole-body DWI at
higher field strength. In this respect, the reintroduction of the
slice-selection gradient reversal (SSGR) technique is very
promising [57, 58]. The SSGR technique uses two slice-
selection gradients of opposing polarity for the 90° excitation
pulse and the 180° refocusing pulse in a spin-echo EPI
sequence for diffusion sensitization. The SSGR technique
exploits the high sensitivity of EPI to chemical shift artefacts
(water-fat shift) in the phase-encoding direction due to the
relatively low bandwidth in that orientation; water signal will
be completely preserved, but only fat signal that was exposed
to both the excitation pulse and the refocusing pulse in the
centre of the water slice will contribute to image formation.
Since chemical shift artefacts are more pronounced at higher
field strengths, fat signal can be significantly reduced or even
completely eliminated using the SSGR technique at field
strengths ≥3 .0-T. Furthermore, unlike spectral fat saturation
and STIR, the SSGR technique does not prolong scan time,
nor does it increase SAR [57, 58].
Another promising development that was recently
implemented at a clinical 3.0-T system is the multi-source
RF transmission technology [54]. Using this technology,
independent RF pulses are sent; this improves image
uniformity and consistency compared to single-source RF
transmission that may suffer from dielectric resonance
effects at high field strength. Furthermore, local RF
deposition (SAR) can be reduced, allowing for faster
scanning [54]. Thus, although 1.5-T systems still provide
the best and most reproducible image quality, eventually it
is expected that whole-body DWI at 3.0-T will become
possible in routine clinical practice.
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Shifting gears in whole-body molecular imaging
The discrimination between normal-sized non-malignant
lymph nodes and normal-sized lymphomatous lymph nodes
is still an unsolved issue in DWI. This is because both
normal and malignant lymph nodes are highlighted at DWI,
and ADC measurements have not yet been shown to
discriminate [31]. Ultrasmall superparamagnetic iron oxide
(USPIO)-enhanced MRI was introduced in the early 1990s
as a promising imaging modality for evaluating lymph
nodes, allowing for the identification of malignant nodal
infiltration independent of lymph node size [59, 60].
Intravenously administered USPIOs are taken up by macro-
phages in the reticuloendothelial system, predominantly
within the lymph nodes, but also in Waldeyer ring, spleen
and bone marrow. Normal homogeneous uptake of USPIOs
in nonmetastatic lymph nodes shortens the T2 and T2*
values, turning these lymph nodes hypointense on T2- and
T2*-W images, whereas malignant lymph nodes lack
uptake and remain hyperintense [60]. USPIO-enhanced
lymphography has been shown to achieve higher diagnostic
precision than conventional, unenhanced MRI for the
detection of lymph nodes metastases of various tumours
[61]. However, conspicuity and detectability of lymph
nodes is relatively low in USPIO-enhanced MRI. Conse-
quently, image interpretation can be very time consuming,
and malignant lymph nodes of small size may be missed.
Furthermore, one image dataset before and one image
dataset after USPIO administration has to be obtained, that
poses an extra burden on the patient, and on logistic and
financial resources.
Performing DWI after USPIO administration may
overcome the disadvantages of DWI and conventional
(T2- or T2*-W) USPIO-enhanced MRI alone. Theoretical-
ly, in USPIO-enhanced DWI only malignant lymph nodes
will be highlighted; the high lymph node-to-background
contrast will reduce image interpretation time and will
obviate the need to acquire an additional dataset of images
before USPIO administration. The feasibility of this new
concept has recently been proven in patients with urinary
bladder and prostate cancer (although attention should be
paid to possible oversuppression by USPIOs as a result of
which micrometastases may be missed); an extension of
this concept to the entire body (i.e. USPIO-enhanced
whole-body DWI) may provide a highly accurate method
for the determination of extent of nodal involvement in
patients with malignant lymphoma [62]. An important
additional advantage of USPIO-enhanced whole-body
DWI over whole-body DWI alone is suppression of signal
from the normal Waldeyer ring, spleen and normal or
hyperplastic red bone marrow, against which lymphoma-
tous lesions in these organs will theoretically be high-
lighted [63].
Another promise for the future is the development of
whole-body PET/MRI systems [64]. Although several
technological difficulties have to be solved in the design
of a fully integrated whole-body PET/MRI system (includ-
ing the issues of electromagnetic interference between the
two systems and MRI-based attenuation correction), and
high (development) costs have to be taken into account, the
integrated use of whole-body DWI and FDG-PET may be
of interest in (paediatric) patients with malignant lymphoma
[64]. For example, FDG-PET may increase diagnostic
performance of DWI alone in several areas, including
(normal-sized) lymph nodes, spleen, and bone marrow [7,
65, 66]. Furthermore, FDG-PET may be a powerful adjunct
to whole-body MRI/DWI in restaging malignant lympho-
ma; restaging performance of whole-body MRI/DWI is still
unknown, but FDG-PET has already proven to be of value
in diagnosing persistent or recurrent disease [7, 67, 68]. On
the other hand, an area where DWI may clearly be of
advantage compared to FDG-PET is the urinary tract.
Normal FDG accumulation in the renal collecting system,
ureters and bladder may limit the use of FDG-PET in the
evaluation of renal, paraortic, and pelvic lesions, whereas
DWI does not have this disadvantage [69]. Another
advantage of DWI over (FDG) PET is its superior spatial
resolution. Furthermore, although most childhood NHLs
are FDG-avid, DWI allows visualization of certain subtypes
of NHLs that are not FDG-avid [7, 8].
Conclusion
Whole-body MRI and whole-body DWI in particular,
provides a radiation-free alternative for staging malignant
lymphoma in children. Whole-body DWI may potentially
facilitate image interpretation and increase sensitivity of
conventional (T1- and T2-W) whole-body MRI alone.
Nevertheless, there is a strong need for comparative
studies with FDG-PET/CT before definitive conclusions
can be made regarding its value in the diagnostic
management of malignant lymphoma. Integrating
whole-body DWI with other molecular imaging strate-
gies, including USPIO-enhanced imaging and FDG-PET,
is expected to further increase its staging performance in
malignant lymphoma.
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